Logo

BMS Reports the Updated Data from P-III (CheckMate -73L) Study of Opdivo for Non-Small Cell Lung Cancer

Share this
BMS

BMS Reports the Updated Data from P-III (CheckMate -73L) Study of Opdivo for Non-Small Cell Lung Cancer

Shots:

  • The P-III (CheckMate -73L) study compares Opdivo + concurrent chemoradiotherapy (CCRT) followed by Opdivo + Yervoy (Arm A) or Opdivo alone (Arm B) to CCRT alone followed by durvalumab (Arm C) in treatment-naïve unresectable locally advanced stage III NSCLC patients (n=925)
  • The 1EP of the study includes PFS for Arm A vs Arm C while the 2EPs include OS, PFS, ORR, TTR, DoR, and further safety & effectiveness
  • The study did not reach the 1EP of PFS and the AEs across Arm A were consistent. The full evaluation of the study continues and the data will be presented to the scientific community

Ref: BMS | Image: BMS

Related News:- BMS Reports the US FDA’s Acceptance of BLA for Opdivo to Treat Clear Cell Renal Cell Carcinoma

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions